v3.26.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
CURRENT ASSETS    
Cash and cash equivalents $ 4,548 $ 2,169
Restricted Cash 3 240
Clinical trial services asset [1] 539 0
Trade receivables, net of credit losses of $209 and $192, as of September 30, 2026 and December 31, 2025, respectively 7,649 6,138
Prepaid expenses and other current assets 2,261 1,528
Inventories 6,697 5,732
Total current assets 21,697 15,807
LONG-TERM ASSETS    
Restricted cash and other long-term assets 484 209
Clinical trial services asset [1] 269 0
Operating lease right-of-use assets 2,441 1,544
Property and equipment, net 463 585
Intangible Assets 409 0
Goodwill 4,755 4,755
Total long-term assets 8,821 7,093
Total assets 30,518 22,900
CURRENT LIABILITIES    
Trade payables 5,838 5,590
Employees and payroll accruals 1,513 1,442
Deferred revenues 965 920
Convertible promissory note [2] 0 2,803
Current maturities of operating leases liability 762 425
Other current liabilities 1,777 859
Total current liabilities 10,855 12,039
LONG-TERM LIABILITIES    
Convertible promissory notes, net [3] 7,133 0
Financing liabilities 1,988 0
Deferred revenues 1,319 1,233
Non-current operating leases liability 1,712 1,159
Other long-term liabilities 244 61
Total long-term liabilities 12,396 2,453
Total liabilities 23,251 14,492
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders’ equity:    
Share capital Ordinary share Authorized: 100,000,000 shares at September 30, 2026 and 75,000,000 December 31, 2025; Issued: 2,886,603 and 1,572,319 shares at September 30, 2026 and December 31, 2025, respectively; Outstanding: 2,838,715 and 1,524,431 shares as of September 30, 2026 and December 31, 2025 respectively [4] 0 9,418
Additional paid-in capital 322,573 286,932
Treasury Shares at cost, 47,888 ordinary shares at September 30, 2026 and December 31, 2025 [4] (3,203) (3,203)
Accumulated deficit (312,103) (284,739)
Total shareholders' equity 7,267 8,408
Total liabilities and shareholders' equity $ 30,518 $ 22,900
[1] Represents amounts recognized in connection with a clinical trial services with Oramed Pharmaceuticals Inc., a related party. See Notes 6 and 10.
[2] Represents amounts due to Oramed Pharmaceuticals Inc. as of December 31, 2025. Oramed became a related party upon completion of the March 2026 transaction. See Note 9.
[3] Includes $4,387 thousand attributable to Oramed Pharmaceuticals Inc., a related party as of September 30, 2026. See Note 9.
[4] Reflects the one-for-twelve reverse share split that became effective on February 24, 2026. See Note 8a.